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Available online 29 December 2013Abstract Endothelial progenitor cells (EPCs) may contribute to neurovascular repair after stroke and neurodegeneration. A
key step in this process should involve adhesive interactions between EPCs and the targeted cerebral endothelium. Here, we
tested the hypothesis that reactive astrocytes may play a critical role in enhancing adhesive interactions and transmigration of
EPCs across cerebral endothelial cells. Transiently seeding EPCs onto a monolayer of RBE.4 rat brain endothelial cells resulted
in a time-dependent adherence between the two cell types. Blocking β2 integrins on EPCs or blocking the receptor for
advanced glycation endproducts (RAGE) on endothelial cells significantly decreased EPC-endothelial adherence. Next, we
tested whether reactive astrocytes can enhance this process by growing EPCs, brain endothelial cells and astrocytes together in
a transwell co-culture system. The presence of reactive astrocytes in the lower chamber significantly promoted adherence
between EPCs and endothelial cells in the upper chamber. This process involved the release of soluble HMGB1 from reactive
astrocytes that then upregulated endothelial expression of RAGE via Egr1 signaling. Directly adding HMGB1 to the transwell
system also promoted EPC-endothelial adhesion and accelerated EPC transmigration into the lower chamber. These initial
findings provide proof-of-concept that reactive astrocytes promote crosstalk between cerebral endothelium and EPCs. Further
investigation of this phenomenon may lead to a better understanding of cell–cell interactions required for neurovascular
recovery after stroke.
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For many years, CNS was considered to be an isolated and
immune-privileged organ. However, it is now recognized
that systemic responses in blood contribute to bi-directional
signaling with the CNS after injury. Integrated responses in
neurons, glia, brain blood vessels, and circulating peripheral
cells all contribute to the pathogenesis of injury ander B.V. All rights reserved.
532 K. Hayakawa et al.mechanisms of repair after stroke and trauma (Moskowitz et
al., 2010).
A specific set of peripheral cells that have been implicated
comprise the population of circulating endothelial progenitor
cells (EPCs). EPCs have been viewed as adult stem cells that
can play an important role in tissue vascularization and
endothelium homeostasis after CNS damage and neurodegen-
eration (Rouhl et al., 2008; Nan et al., 2005). EPCs are highly
migratory and may be attracted to injured or diseased brain
areas, where they are thought to mediate angiogenesis,
vasculogenesis and neurovascular tissue repair (Fan et al.,
2010; Sobrino et al., 2007). The underlying mechanisms are
not fully understood, and many potential mediators continue
to be investigated, including “homing signals” such as stromal
cell-derived factor-1 (SDF-1) (Lapidot, 2001) and “cell–cell
interactive signals” such as β1- and β2- integrins (Shyu et al.,
2006; Chavakis et al., 2005). However, what tends to be
missing from these previous models is the consideration of
cross-talk signals from other cells in the brain.
We recently showed that, by acting as sensors of
neurovascular injury, astrocytes could augment EPC-mediated
neurovascular remodeling after stroke and brain injury
(Hayakawa et al., 2012, 2013). But what are the molecular
mechanisms that underlie this ability of astrocytes to promote
EPC function during CNS repair? In the present study, we
examined the hypothesis that reactive astrocytes can release
HMGB1, a member of the damage-associated-molecular-
pattern (DAMP) family of proteins that subsequently enhances
adhesive interactions and increases transmigration of EPCs
across targeted brain endothelium.Methods
All experiments were performed following an institutionally
approved protocol in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals.Chemicals
Rat recombinant IL-1β and human recombinant HMGB1 were
purchased from Sigma-Aldrich.Antibodies
CD34, Flk-1 (VEGFR2) and Egr1 antibodies, control goat IgG
and mouse IgG were purchased from Santa Cruz Biotechnol-
ogy. RAGE antibody was purchased from R&D systems.
HMGB1 antibody (Abcam) and integrin antibodies (CD11a,
CD11b, and CD18, BD biosciences) were purchased from each
company. Antibodies against RAGE, CD11a, CD11b, and CD18
have neutralizing capacity.Cell cultures
Rat brain endothelial cells
A rat brain microendothelial cell line, RBE.4 were maintained
in EBM-2 containing EGM-2MV SingleQuots kit onto collagen-
coated 25 cm2 flasks at a density of 2 × 105 cells/cm2
incubated in a 5% CO2 incubator at 37 °C. RBE.4 wasdissociated by trypsinization and then reseeded on collagen
I-coated 24 well plates for cell adhesion assay.Rat endothelial progenitor cells
Spleens were used for the obtaining of EPCs as described as
before (Rosell et al., 2009). For each independent experiment,
spleens from 11 to 12 week old Sprague–Dawley (SD) rats were
kept in PBS solution. Under the hood, spleens were mechan-
ically minced, placed at 37 °C for 15 min in EPCs lysis buffer
and run through a 40-μm nylon membrane to obtain cell
suspension. Mononuclear cells (MNCs) were obtained by density
gradient centrifugation with Ficoll-Paque Plus (Amersham
Biosciences Corp). Isolated MNCs were shortly washed with
red blood cells lysis solution and gently washed twice with
complete growth media EGM-2MV (Lonza). MNCs were finally
resuspended in EGM-2MV and 3 × 107 MNCs per well were
seeded on collagen I-coated six-well plates (Becton Dickinson
Labware) and incubated in a 5% CO2 incubator at 37 °C. Under
daily observation, first media change was performed 3–4 days
after plating. Early EPCs were used for each independent
experiment between 5 and 7 days after seeding.Primary astrocyte cultures
Primary astrocyte cultures were prepared from cerebral
cortices of 2-day-old neonatal Sprague–Dawley rats as
described as before (Arai et al., 2003). Briefly, dissociated
cortical cells were suspended in Dulbecco's modified Eagle
medium (NBM, Life Technology) containing 25 mM glucose,
4 mM glutamine, 1 mM sodium pyruvate, and 10% fetal bovine
serum and plated on uncoated 25 cm2 flasks at a density
of 6 × 105 cells/cm2. Monolayers of type 1 astrocytes were
obtained 12–14 days after plating. Non-astrocytic cells such as
microglia and neurons were detached from the flasks by shaking
and removed by changing the medium. Astrocytes were
dissociated by trypsinization and then reseeded on uncoated
6- and 24-well plates at a density of 1 × 105 cells/cm2.Primary monocytes/macrophages cultures
Monocytes/macrophages were isolated from rat peritoneal
cavity. After collecting cells from the cavity, 1 × 105 cells
per well were seeded on non-coated six-well plates and
grown in RPMI medium 1640 containing 0% FBS, 1% penicillin/
streptomycin. Twenty four hours later, attached cells were
used as a mix of monocytes/macrophages.EPCs labeling
Cells were incubated with 5 μg/ml 1, 1-dioctadecyl-3, 3, 3,
3-tetramethylin-docarbocyanine perchlorate (DiI)-labeled
acetylated low density lipoprotein (ac-LDL; Molecular
Probes) at 37 °C for 120 min in EGM-2 MV.Monocytes/macrophages labeling
Cells were incubated with 3 μM calcein AM at 37 °C
for 30 min in RPMI medium 1640 containing 10% FBS, 1%
penicillin/streptomycin.
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After 24 hours incubation with or without IL-1β (1, 10,
and 100 ng/ml), ac-LDL labeled EPCs (1 × 104 cells/well)
were coincubated with RBE.4 monolayer at 37 °C for 10, 30,
60 and 90 min. Calcein AM-labeled monocytes/macrophages
(1 × 105 cells/well) were coincubated with RBE.4 mono-
layer 37 °C for 20 min. Then, adhered EPCs or monocytes/
macrophages were fixed with 4% paraformaldehyde for
10 min and were washed three times with ice-cold
phosphate-buffered saline (PBS) to remove non adherent
cells. The numbers of adhered cells were quantified by
counting the number of ac-LDL positive cells or calcein AM
positive cells.
In vitro trans-endothelial migration assay
Rat brain endothelial cells (RBE.4) (1 × 105 cells/well) were
seeded on polycarbonatemembrane (3-μmpore filters, Corning
Costar) coated with collagen I to obtain confluent endothelial
monolayers. Ac LDL-labeled EPCs (1 × 105 cells/well) were
placed in the upper chamber on top of the RBE.4 monolayer.
The chambers were placed in a 24-well culture plate containing
IL-1β (1 ng/ml) or recombinant HMGB1 (10 ng/ml) or rat
cortical astrocytes. After 24 h of incubation at 37 °C, the
lower side of the filter was washed with PBS and fixed with 4%
PFA. Labeled EPCs migrating into the lower chamber were
directly counted in 4 random microscopic fields.
Western blot analysis
Cultures were rinsed twice with PBS and cell membrane
extracts were collected according to the method of
ProteoExtract Kit (Calbiochem). Samples were heated
with equal volumes of SDS sample buffer (Novex) and 10%
2-mercaptoethanol at 95 °C for 5 min, and then each sample
was loaded onto 4–20% Tris-glycine gels. After electrophoresis
and transferring to polyvinylidene difluoride membranes
(Novex), the membranes were blocked in Tris-buffered saline
containing 0.1% Tween 20 and 0.2% I-block (Tropix) for 60 min
at 4 °C. Membranes were then incubated overnight at 4 °C
with primary antibodies. After incubation with peroxidase-
conjugated secondary antibodies, chemiluminescence was
enhanced (GE Healthcare). Optical density was assessed
using the NIH Image analysis software.
Immunohistochemistry
Cells were washed with ice-cold PBS (pH 7.4), followed by
4% paraformaldehyde for 10 min. After being washed three
times in PBS containing 0.1% Triton X-100, they were
incubated with 3% bovine serum albumin (BSA) in PBS for
1 h. Then cells were incubated with primary antibodies at
4 °C overnight. After washing with PBS, they were incubated
with secondary antibodies (1:400; Jackson ImmunoResearch)
for 1 h at room temperature. Finally, nuclei were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI), and cov-
erslips were placed. Immunostaining was analyzed with a
fluorescence microscope (Olympus BX51) interfaced with a
digital charge-coupled device camera and an image analysis
system.Egr1 siRNA transfection in rat brain endothelial cells
Control siRNA and Egr1 siRNA were obtained from Santa Cruz
Biotechnology. Control siRNA (sc37007) consists of a scram-
bled sequence that will not lead to the specific degradation of
any known cellular mRNA. Egr1 siRNA (sc270177) is a pool of 3
target-specific 19-25nt siRNAs designed to knock down gene
expression. The sequences for rat Egr1 siRNAs are designed
as followed; Sequence 1: 5′-CAGCGCUUUCAAUCCUCAAtt-3′,
Sequence 2: 5′-CCAUGAUCCCUGACUAUCUtt-3′, Sequence 3:
5′-CUCCACUAUCCACUAUCAAtt-3′. siRNAs were prepared ac-
cording to the transfection protocol for cell cultures from
Santa Cruz Biotechnology. Briefly, siRNA transfection reagent
mixture of 1 ml (Transfection reagent, sc-29528, Transfection
medium, sc36868) was co-incubated with RBE.4 for 6 h in a 5%
CO2 incubator at 37 °C, and then same amount of EBM-2 1%
FBS was added. An additional incubation was performed for
18 h, and then the procedure for conditioned media was
carried on.
Statistical analysis
All of experiments were blinded and performed in duplicate,
repeated 3–5 times independently. GraphPad Prism 5 was
used overall statistical analysis in this study. Results were
expressed as mean ± SD. When only two groups were
compared, Student's t-test was used. Multiple comparisons
were evaluated by Tukey's test after one-way ANOVA or
two-way ANOVA. P b 0.05 was considered to be statistically
significant.
Results
EPC-endothelial adherence is mediated via
β2-integrin-RAGE interactions
After isolation from rat spleen, early EPCs were positive
for representative markers including Flk1 and CD34 at 5
days after seeding (Fig. 1a). Adhesion of diI-ac-LDL-labeled
EPCs was assessed by counting labeled cells that remain
attached after a transient co-incubation onto a monolayer of
RBE.4 rat brain endothelial cells (Fig. 1b–c). When EPCs
were stimulated with low concentrations of IL-1β for 24 h
prior to incubation, adherence was significantly increased
(Fig. 1c–d). Immunocytochemistry and western blots sug-
gested that the increased adherence may be due to an
IL-1β-induced upregulation of β2-integrin expression in EPCs
(Fig. 2a–b). Blockade with anti-CD18 (β2-integrin) antibod-
ies in EPCs decreased their adhesion to the endothelial
monolayer (Fig. 2c). Conversely, adding an anti-RAGE
antibody onto the RBE.4 endothelial cells also decreased
EPC adhesion (Fig. 2d). Taken together, these data suggest
that RAGE on endothelial cells binds β2-integrin on EPCs,
thus facilitating their adhesive interactions.
Reactive astrocytes enhance EPC adherence via
HMGB1-induced upregulation of endothelial RAGE
Astrocytes were stimulated with IL-1β, and as expected, this





50 µm 50 µm
dc
Flk1/DAPI CD34/DAPI
10 µm 10 µm
Figure 1 IL-1β-stimulated EPCs was enhanced the adhesive interaction to brain endothelial cells. (a) Early EPCs (5 days after seeding)
were identified by representativemarkers including Flk1 and CD34. (b) Ac-LDL labeled EPCs adhered to rat brain endothelial cells (RBE.4).
(c) The number of attached EPCs to RBE.4 monolayer was increased in a time-dependent manner and IL-1β (10 ng/ml)-stimulated EPCs
showed more adherent ability to endothelial monolayer. ⁎P b 0.05, ⁎⁎P b 0.01 vs normal EPCs. (d) Low concentration of IL-1β (1 and
10 ng/ml) stimulated EPCs and significantly augmented their adhesive interaction with endothelium. ⁎P b 0.05 vs normal EPCs.
534 K. Hayakawa et al.expression of GFAP and vimentin (Fig. 3a), and promoted
the release of HMGB1 into the conditioned media (Fig. 3b).
Quantitation revealed that IL-1β-stimulated astrocytes
released approximately 1–2 ng/ml of HMGB1. To ascertain
whether reactive astrocytes can augment adhesion of EPCs
onto RBE.4 endothelial cells, a triple-culture was performed
with a transwell co-culture system (Fig. 3c). When reactive
astrocytes were grown in the lower chamber, adhesion of
EPCs onto endothelial cells was significantly increased in the
upper chamber (Fig. 3d). To check the specificity of this
phenomenon, monocytes/macrophages were also used in a
triple-culture model (Fig. 3e). IL-1β itself enhanced adhe-
sive interactions between monocytes/macrophages on en-
dothelial cells but cell adherence was not significantly
augmented by the presence of IL-1β-stimulated astrocytes





















Figure 2 IL-1β enhanced adhesive interaction between β2-integ
showed enhancement of β2-integrin expression in EPCs after treatm
accumulation of β2-integrin in EPCs membrane. (c) Blocking with a
their adhesion, but anti-CD11a blockade had no effects. ⁎P b 0.05
adherence. These data support the idea that β2-integrin on EPCs are
antibody in RBE.4 also decreased EPC adhesion. ⁎⁎P b 0.01 vs normalHMGB1 was tested by removing astrocytes from the
transwell system completely and adding exogenous HMGB1
(0.1, 1, 10 ng/ml) into the lower chamber instead (Fig. 4a).
This range of exogenous HMGB1 was chosen based on the
levels of HMGB1 released by stimulated astrocytes. HMGB1
directly promoted adhesion between EPCs and the RBE.4
endothelial cells in the upper chamber (Fig. 4b). This effect
may bemediated in part by the ability of HMGB1 to upregulate
RAGE levels in the endothelial monolayer over time (Fig. 4c).
HMGB1-induced upregulation of endothelial RAGE was depen-
dent on Egr1, which is known to activate key promoter regions
on the RAGE gene (Fig. 5a). When siRNA was used to suppress
Egr1 signaling (Fig. 5b), the ability of HMGB1 to upregulate
RAGE levels on RBE.4 brain endothelial cells was significantly
reduced (Fig. 5c). Consistent with this suppression of
endothelial RAGE, siRNA against Egr1 significantly decreasedd
* *
rin in EPCs and endothelium RAGE. (a) Immunocytochemistry
ent with IL-1β (10 ng/ml). (b) Western blot analysis confirmed
nti-CD18 (β2-integrin) antibody in EPCs significantly decreased
vs normal EPCs adherence, #P b 0.05 vs IL-1β-stimulated EPCs
involved in adhesion. (d) Conversely, blocking with an anti-RAGE
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Figure 3 Reactive astrocytic HMGB1 enhanced EPCs adherence to RBE.4 monolayer. (a) Western blot analysis showed that IL-1β
increased reactive astrocytes markers (GFAP and vimentin) in a concentration-dependent manner. (b) Lower concentration of IL-1β (0.1
and 1 ng/ml) induced the release of HMGB1 in astrocytes as described as before (Hayakawa et al., 2010b). *P b 0.05 vs IL1β 0 ng/ml. (c)
Co-culture between rat cortical astrocytes in the lower chamber and rat brain endothelial cells in the upper chamber was performed for
24 h. Then, labeled EPCs were added into the upper chamber for 45 min. (d) IL-1β (1 ng/ml)-stimulated reactive astrocytes enhanced
EPCs adherence to RBE.4 monolayer. ⁎⁎P b 0.01 vs control group. (e) Calcein AM-labeled monocytes/macrophages were added into the
upper chamber for 20 min. (f) IL-1β (1 ng/ml) itself increased adhesive interaction of monocytes/macrophages. IL-1β-stimulated
reactive astrocytes (IL-1β-A) did not enhance monocytes/macrophages adherence to RBE.4 monolayer. A; astrocytes.
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stimulation (Fig. 5d–e).Reactive astrocytes enhance EPC transmigration
After EPCs adhere onto endothelial cells, they may also
transmigrate. Hence, we asked whether reactive astrocytes
could also promote EPC transmigration in our transwell culture
system (Fig. 6a). When IL-1β-stimulated reactive astrocytes
were present in the lower chamber, diI-ac-LDL-labeled EPCs




Figure 4 Soluble HMGB1 promoted EPCs adherence through up-regu
prepared onto collagen I-coated transwell and HMGB1 (10 ng/ml) wa
induced more adhesive interaction between EPCs and endothelium. ⁎⁎
chamber increased endothelium RAGE expression in a concentration-dthe RBE.4 brain endothelial monolayer growing in the upper
chamber (Fig. 6b–c). In the absence of astrocytes, EPC
transmigration across the endothelial monolayer was also
induced by directly adding exogenous HMGB1 into the empty
lower chamber (Fig. 6d).
Discussion
Our study provides in vitro proof-of-concept that reactive
astrocytes play a key role in promoting EPC-brain endothe-
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Figure 5 Egr1 signaling pathway supports endothelium RAGE expression and EPCs adherence. (a) Western blot analysis showed that
HMGB1 (10 ng/ml) significantly increased Egr-1 expression in RBE.4 in a time-dependent manner. *P b 0.05 vs HMGB1 0 min. (b) Egr-1
siRNA transfection successfully reduced Egr-1 expression induced by HMGB1 (10 ng/ml) after 60 min. (c) Rat brain endothelium RAGE
expression 24 h after HMGB1 (10 ng/ml) stimulation significantly attenuated by Egr-1 siRNA transfection. *P b 0.05 vs control siRNA
without HMGB1 stimulation. (d) RBE.4 monolayer treated with Egr-1 siRNA or control siRNA was prepared onto collagen I-coated
transwell. Recombinant HMGB1 was added into the lower chamber for 24 h. Then, labeled EPCs were added into the upper chamber
for 45 min. (e) Egr-1 siRNA transfection significantly reduced EPCs adherence rate. ⁎P b 0.05 vs control siRNA-treated group.
536 K. Hayakawa et al.demonstrate that (i) β2 integrin-RAGE interactions, (ii)
reactive astrocytes release HMGB1 that promotes EPCs












Figure 6 HMGB1 induced trans-endothelial migration of early EPCs
onto the upper chamber. After adding recombinant IL-1β protein
migration was allowed for 24 h. (b) Representative images of the tran
are indicated by DAPI. (c) IL-1β-stimulated astrocytes strongly attra
**P b 0.01 (d) Data analysis showed that HMGB1 (10 ng/ml) itself enupregulating RAGE receptors on brain endothelial cells, and
(iii) after adherence, HMGB1 also promotes EPC transmi-
gration across brain endothelial monolayers. Hence, EPCAstrocyte IL1β-stimulatedastrocyte
P<0.01
. (a) Rat brain endothelial cells (RBE.4) monolayer was prepared
in rat cortical astrocytes in the lower chamber, labeled EPCs
s-endothelial migration of diI-ac LDL labeled EPCs (red). Nuclear
cted EPCs compared with normal astrocytes or IL-1β. *P b 0.05,
hanced trans-endothelial migration in early EPCs. *P b 0.05.
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cell signals at the neurovascular interface.
EPCs are well known to play a major role in the pathology
of diverse vascular disorders, including traumatic brain
injury and stroke. The beneficial effects of EPCs have been
described in rat models of focal cerebral ischemia (Fan et
al., 2010; Taguchi et al., 2004). In humans, circulating levels
of EPCs tend to track the temporal profile of recovery from 7
to 14 days after stroke onset (Navarro-Sobrino et al., 2010,
2011). More recently, soluble factors secreted from EPCs
such as VEGF, FGF-beta, and PDGF-BB may be considered as
positive mediators to promote angiogenesis and neurogenesis
after stroke (Rosell et al., 2013). Although the therapeutic
potential of EPCs in stroke has been suggested, it remains
unclear how EPCs target the central nervous system. Our
present findings may now provide a mechanism that directly
links central crosstalk between reactive astrocytes and brain
endothelial cells with a peripheral response in the systemic
EPC response. Further dissection of these molecular pathways
may lead to therapeutic approaches to potentially amplify
these potentially beneficial EPC responses in damaged or
diseased brain.
RAGE expression usually is low under normal condition but
enhanced expression of RAGE has been observed in diabetic
vasculature and other inflammatory diseases (Huttunen et al.,
2002; Hori et al., 1995; Bierhaus et al., 2005). RAGE is not only
involved in the regulation of cellular activation, but also
functions as an adhesion receptor on endothelial cells.
Enhancement of RAGE expression can promote the recruit-
ment of leukocytes across endothelial barriers through its
interaction with myeloid cells expressing the β2-integrin
macrophage receptor 1 (Mac-1) (Rouhiainen et al., 2004). In
a static in vitro assay, RAGE was found to bind to the I-domain
of Mac-1 with Kd 80–100 nM (Chavakis et al., 2003). Here, our
findings may provide another example of how upregulations in
brain endothelial RAGE may bind with β2-integrin in EPCs,
thus promoting their central accumulation.
In this study, our findings suggest that the ability of reactive
astrocytes to promote EPC response may be due to the release
of HMGB1. As a damage-associated-molecular-pattern (DAMP)
mediator, HMGB1 is traditionally known as a nuclear and
cellular danger signal (Lotze & Tracey, 2005). Large elevations
in HMGB1 can be deleterious after stroke and brain injury
(Kim et al., 2006). However, more recently, it is recognized
that HMGB1 can exert different functions depending on its
cellular localization. When large amounts are passively
released from damaged cells, HMGB1 worsens neuroinflam-
mation and brain injury (Kim et al., 2006). But when lower
levels of HMGB1 are actively secreted from reactive
astrocytes, beneficial actions can be detected (Hayakawa
et al., 2012). Upon release, extracellular HMGB1 binds to
its putative receptors (RAGE, TLR2, TLR4), and induces series
of signaling pathways in response to the original damage.
Recently, we showed that suppressing HMGB1 in reactive
astrocytes might worsen neurovascular recovery after focal
ischemia in mice (Hayakawa et al., 2010a, 2012). The present
study may provide a specific mechanism for this phenomenon
that directly links the reactive astrocyte and endothelial cells
within the neurovascular unit to a pro-recovery EPC response.
Taken together, our findings support a novel mechanism
whereby reactive astrocytes release HMGB1 that upregulates
RAGE receptors on brain endothelial cells, thus augmentingβ2-integrin-mediated EPC adhesion and transmigration. How-
ever, there are several caveats worth keeping in mind. First,
we mainly focus on EPCs and we could not detect clear
differences in monocytes/macrophages. Recent study dem-
onstrates that TLR4 signaling stimulated by lipopolysaccharide
increased microvascular CD200 expression, a cell surface
glycoprotein which induces immunosuppressive activity, and
CD200 receptor agonist inhibited macrophages interaction to
endothelial cells. (Ko et al., 2009) HMGB1 can also stimulate
TLR4 in endothelial cells thus the attachment of monocytes/
macrophages may not be augmented through CD200 signaling.
Nevertheless, how all blood cells interact as theymove toward
a diseased neurovascular unit remains to be elucidated.
Second, other adherence factors and receptors may also
contribute. For example, HMGB1 is known to increase
expression of vascular cell-adhesion molecule 1 (VCAM-1),
intercellular adhesionmolecule 1 (ICAM-1) and endothelial-cell
selectin (Lotze & Tracey, 2005; Fiuza et al., 2003). Our focus
was on RAGE, but how multiple signals coordinate with
multiple receptors in EPCs and endothelium will be a very
complicated system that must be further investigated. Third,
our in vitro model is limited in its ability to fully replicate in
vivo pathophysiology. For example, our models use standard
neonatal and very young cell cultures. But of course, disease
tends to occur in aged CNS. How our hypothesis of endothelial
RAGE and β2-integrin in EPCs contribute to neurovascular
remodeling after stroke should be eventually addressed with in
vivo studies. Finally, our endpoints are all cell-based and not
functional. Whether EPCs has specific phenotype for transmi-
gration is unclear. In addition, during transmigration, EPCsmay
be stimulated with many factors from both the brain
parenchyma and circulating factors in blood thus the pheno-
type might be changed after transmigration. Future studies
should be required to determine the functional sequelae of
EPCs that have been amplified by astrocyte-endothelial
crosstalk.Conclusion
The concept of the neurovascular unit, i.e. cell–cell signaling
between neuronal, glial and vascular compartments, has
provided a powerful framework for investigating the mecha-
nisms of acute injury and delayed recovery after stroke, brain
injury and neurodegeneration (Iadecola, 2004; Zlokovic, 2010).
This study suggests that signaling at the neurovascular interface
may also play a key role in promoting EPC-mediated peripheral
responses. By upregulating RAGE on affected endothelial cells,
reactive astrocytes may augment EPC adherence and trans-
migration. This phenomenonmay comprise a novelmechanism
whereby crosstalk between reactive astrocytes and cerebral
endothelium augments EPC responses for neurovascular
recovery in damaged or diseased brain. Further studies are
warranted to dissect the in vivo consequences of this
phenomenon in animal models of stroke, brain injury and
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